# F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus

> **NCT06468683** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Simnova Biotechnology Co.,Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Lupus Erythematosis

## Interventions

- **BIOLOGICAL:** After preconditioning with chemotherapy, F01 will be evaluated.

## Key facts

- **NCT ID:** NCT06468683
- **Lead sponsor:** Shanghai Simnova Biotechnology Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-15
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468683, "F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06468683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*